Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients
Launched by PEKING UNIVERSITY FIRST HOSPITAL · May 18, 2011
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Objective A cross-over study is designed to elucidate if oral vitamin C supplementation can reduce inflammation status in maintenance dialysis patients with low vitamin C level and high CRP level.
Patients, Methods and Expected results Patients About 100 dialysis patients were recruited. Patients will be divided into two groups, and will be followed for at least 6 months.
Methods Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral V...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients receiving maintenance hemodialysis or continuous ambulatory peritoneal dialysis, and dialysis vintage more than 3 months
- • Patients aged between 18 and 80 years older
- • VitC \< 4ug/ml and hsCRP \> 3mg/L
- • for HD patients, Kt/V \> 1.2 per session, at least 3 sessions per week, 4 hours per session
- • for PD patients, Kt/V \> 1.7 per week
- • age and gender matched health control
- Exclusion Criteria:
- • Active autoimmune disease, malignancy, hepatitis
- • Positive HIV serology
- • Any kind of acute infection within one month, chronic infection
- • Currently using steroids or immune-suppressants
- • Pregnancy or breast feeding
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Li Zuo, MD
Study Director
Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials